Skip to Content

Money Behind First CRISPR Test? It’s from Internet Billionaire Sean Parker

A next wave of cancer treatments may combine immunotherapy and gene editing.

The first proposed test of CRISPR gene-editing technology in human beings is being funded by Internet billionaire Sean Parker, MIT Technology Review has learned.

The novel cancer treatment, initially disclosed last week, is being reviewed Tuesday by a federal advisory panel in Washington, D.C., and could become the first clinical trial involving CRISPR, the red-hot gene modification technology.

Now we can report that Parker, a 36-year-old whose net worth is estimated at $2.4 billion, is financing the study.

Parker, best known for his role as Facebook’s first president and as co-creator of the pirate music site Napster, splashed into cancer research in April, saying he’d give $250 million in funding to six centers, including one at the University of Pennsylvania, in what he called a “Manhattan project for curing cancer with the immune system.”

Penn confirmed Parker’s charitable foundation would be funding the trial, which will use gene-editing to modify immune system T cells to attack three types of cancer: myeloma, melanoma, and sarcoma.

Sean Parker

Parker’s backing highlights how wealthy Internet entrepreneurs think they can speed up cancer research.  Parker, a one-time hacker whose resume includes a run-in with the FBI, has said he thinks of T cells as being “like little computers” that can be reprogrammed (see "10 Breakthrough Technologies 2016: Immune Engineering").

There’s no shortage of funding for immune therapy. New drugs are able to cure some cases of advanced melanoma; T cell treatments, including some pioneered at Penn, have seen dramatic success against leukemia.

But Parker’s foundation is unusual because it says it will control patents on research it funds and even bring treatments to market. Parker compared the tactic to convincing record labels to license their music to Spotify, the popular legal music-sharing service he also is an investor in.

“What if we had a system where all the [intellectual property] could be shared among the scientists?” he told Dateline NBC in a program that aired in May.

The new cancer treatment developed at Penn uses gene-editing to modify T cells so they more effectively target certain cancers other than leukemia. Penn appears to have filed a patent on the idea last October, according to European patent records.

A proposal for a small safety study will be presented Tuesday by Penn doctors Carl June, Joseph Melenhorst, and Edward Stadtmauer, according to an updated agenda of the Recombinant DNA Advisory Committee, which reviews gene therapy studies.

Up to 15 patients could receive the treatment at three sites: Penn, the University of California, San Francisco, and the MD Anderson Cancer Center. The study involves complex safety issues, such as whether the alterations achieved using gene editing will be accurate enough, and there is no guarantee it will go forward.

The treatment envisions removing a cancer patient's T cells and then re-infusing them a month later following genetic alterations to their DNA designed to cause them to zero in on, and destroy, the tumors.

“One of our key areas of focus is to develop novel approaches to modify T cells to enhance their function,” said Jenifer Haslip, a spokesperson for the billionaire’s nonprofit, called the Parker Institute for Cancer Immunotherapy, headquartered in San Francisco.  

“CRISPR technology provides an opportunity to profoundly manipulate cells,” according to a statement provided by Haslip. “We’re excited to be part of the first clinical effort in the United States to combine these two powerful therapeutic approaches to treat a devastating disease like cancer."

Keep Reading

Most Popular

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

open sourcing language models concept
open sourcing language models concept

Meta has built a massive new language AI—and it’s giving it away for free

Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

images created by Google Imagen
images created by Google Imagen

The dark secret behind those cute AI-generated animal images

Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.